Microparticles for the treatment of disease
Microparticle-bioactive agent based treatments for local treatment of diseased tissues/organs are disclosed.
1. A method of treating a kidney disease comprising:
administering into an artery directly servicing the kidney glomeruli of a patient in need thereof, microparticles comprising a bioactive agent, wherein the microparticles comprise a polymer selected from the group consisting of poly(lactide-co-glycolide-co-caprolactone), poly(lactide-bl-glycolide), poly(lactide-co-glycolide)-bl-polyethyleneglycol, poly(lactide-co-glycolide)-bl-polyethyleneglycol-bl-poly(lactide-co-glycolide), poly(lactide-co-glycolide-co-caprolactone), poly(lactide-co-glycolide-co-hydroxybutyric acid), poly(lactide-co-glycolide-co-trimethylene carbonate), poly(lactide-co-glycolide)-bl-polycaprolactone, poly(lactide-co-glycolide)-bl-poly(hydroxybutyric acid), poly(lactide-co-glycolide)-bl-poly(methylene carbonate), wherein:
less than 10% of the microparticles degrade under physiological conditions to release a therapeutic amount of the bioactive agent within 1 week of administration and more than 90% of the microparticles degrade under physiological conditions to release a therapeutic amount of the bioactive agent within 12 months of administration, and
wherein at least 80% of the microparticles become entrapped in the glomeruli of the kidney upon administration of the microparticles.
2. The method of claim 1 , wherein at least 90% of the microparticles become entrapped in the glomeruli of the kidney first upon administration of the microparticles.
3. The method according to claim 1 , wherein the kidney disease is selected from the group consisting of chronic kidney disease, diabetic nephropathy, focal segmental glomerulosclerosis, IgA Nephritis, lupus nephritis, reflux nephropathy, glomerulonephritis, glomerulonephrosis and polycystic renal disease.
4. The method according to claim 1 , wherein the bioactive agent is selected from the group consisting of a TGF-β pathway inhibitor, a protein kinase C pathway inhibitor, a CTGF pathway inhibitor, an mTOR pathway inhibitor, an antibody against TGF-β, an antibody against CTGF, an angiotensin-converting enzyme inhibitor, an angiotensin II receptor blocker, a diuretic, a beta-blocker, a calcium channel blocker, a vasodilator, a direct renin inhibitor, erythropoietin, an inhibitor of AGE-RAGE signaling, an inhibitor of SMAD signaling, iron and immunosuppresives.
5. The method according to claim 4 , wherein the TGF-β pathway inhibitor is halofuginone.
6. The method according to claim 4 , wherein the protein kinase C pathway inhibitor is reboxistaurin.
7. The method according to claim 4 , wherein the mTOR pathway inhibitor is selected from the group consisting of sirolimus, everolimus, zotarolimus, pimecrolimus, temsirolimus and biolimus.
8. The method according to claim 1 , wherein the microparticles have a mean particle size of about 8 to about 20 microns.
9. The method according to claim 1 , wherein the microparticles have a mean particle size of about 10 to about 15 microns.
10. The method according to claim 1 , wherein the microparticles comprise at least two polymers selected from the group consisting of poly(lactide-co-glycolide-co-caprolactone), poly(lactide-bl-glycolide), poly(lactide-co-glycolide)-bl-polyethyleneglycol, poly(lactide-co-glycolide)-bl-polyethyleneglycol-bl-poly(lactide-co-glycolide), poly(lactide-co-glycolide-co-hydroxybutyric acid), poly(lactide-co-glycolide-co-trimethylene carbonate), poly(lactide-co-glycolide)-bl-polycaprolactone, poly(lactide-co-glycolide)-bl-poly(hydroxybutyric acid), and poly(lactide-co-glycolide)-bl-poly(methylene carbonate).
11. The method according to claim 1 , wherein microparticles comprise a polymer selected from the group consisting of poly(lactide-co-glycolide-co-caprolactone) and poly(lactide-co-glycolide)-bl-polycaprolactone.
12. A method of treating a kidney disease comprising:
administering into an artery directly servicing the kidney glomeruli of a patient in need thereof, microparticles comprising a bioactive agent, wherein the microparticles comprise a polymer selected from the group consisting of poly(lactide-co-glycolide-co-caprolactone), poly(lactide-bl-glycolide), poly(lactide-co-glycolide)-bl-polyethyleneglycol, poly(lactide-co-glycolide)-bl-polyethyleneglycol-bl-poly(lactide-co-glycolide), poly(lactide-co-glycolide-co-hydroxybutyric acid), poly(lactide-co-glycolide-co-trimethylene carbonate), poly(lactide-co-glycolide)-bl-polycaprolactone, poly(lactide-co-glycolide)-bl-poly(hydroxybutyric acid), and poly(lactide-co-glycolide)-bl-poly(methylene carbonate), wherein:
less than 10% of the microparticles degrade under physiological conditions to release a therapeutic amount of the bioactive agent within 1 week of administration and more than 90% of the microparticles degrade under physiological conditions to release a therapeutic amount of the bioactive agent within 12 months of administration,
wherein the microparticles have a mean particle size of about 8 to 20 microns and a narrow polydispersity such that the individual particles in the population differ by no more than ±20%.
13. The method according to claim 12 , wherein the microparticles have a mean particle size of about 10 to about 15 microns.
14. The method according to claim 12 , wherein the kidney disease is selected from the group consisting of chronic kidney disease, diabetic nephropathy, focal segmental glomerulosclerosis, IgA Nephritis, lupus nephritis, reflux nephropathy, glomerulonephritis, glomerulonephrosis and polycystic renal disease.
15. The method according to claim 12 , wherein the bioactive agent is selected from the group consisting of a TGF-β pathway inhibitor, a protein kinase C pathway inhibitor, a CTGF pathway inhibitor, an mTOR pathway inhibitor, an antibody against TGF-β, an antibody against CTGF, an angiotensin-converting enzyme inhibitor, an angiotensin II receptor blocker, a diuretic, a beta-blocker, a calcium channel blocker, a vasodilator, a direct renin inhibitor, erythropoietin, an inhibitor of AGE-RAGE signaling, an inhibitor of SMAD signaling, iron and immunosuppresives.
16. The method according to claim 12 , wherein the mTOR pathway inhibitor is selected from the group consisting of sirolimus, everolimus, zotarolimus, pimecrolimus, temsirolimus and biolimus.
17. The method according to claim 12 , wherein the microparticles comprise at least two polymers selected from the group consisting of poly(lactide-co-glycolide-co-caprolactone), poly(lactide-bl-glycolide), poly(lactide-co-glycolide)-bl-polyethyleneglycol, poly(lactide-co-glycolide)-bl-polyethyleneglycol-bl-poly(lactide-co-glycolide), poly(lactide-co-glycolide-co-hydroxybutyric acid), poly(lactide-co-glycolide-co-trimethylene carbonate), poly(lactide-co-glycolide)-bl-polycaprolactone, poly(lactide-co-glycolide)-bl-poly(hydroxybutyric acid), and poly(lactide-co-glycolide)-bl-poly(methylene carbonate).
18. The method according to claim 12 , wherein microparticles comprise a polymer selected from the group consisting of poly(lactide-co-glycolide-co-caprolactone) and poly(lactide-co-glycolide)-bl-polycaprolactone.
19. A method of treating a kidney disease comprising: administering into an artery directly servicing the kidney glomeruli of a patient in need thereof, microparticles comprising a bioactive agent, wherein:
less than 10% of the microparticles degrade under physiological conditions to release a therapeutic amount of the bioactive agent within 1 week of administration and more than 90% of the microparticles degrade under physiological conditions to release a therapeutic amount of the bioactive agent within 12 months of administration, and wherein at least 99% of the microparticles become entrapped in the glomeruli of the kidney upon administration of the microparticles.
20. A method of treating a kidney disease comprising:
administering into an artery directly servicing the kidney glomeruli of a patient in need thereof, microparticles comprising a bioactive agent, wherein the microparticles comprise a polymer selected from the group consisting of poly(lactide-co-glycolide-co-caprolactone), poly(lactide-bl-glycolide), poly(lactide-co-glycolide)-bl-polyethyleneglycol, poly(lactide-co-glycolide)-bl-polyethyleneglycol-bl-poly(lactide-co-glycolide), poly(lactide-co-glycolide-co-hydroxybutyric acid), poly(lactide-co-glycolide-co-trimethylene carbonate), poly(lactide-co-glycolide)-bl-polycaprolactone, poly(lactide-co-glycolide)-bl-poly(hydroxybutyric acid), poly(lactide-co-glycolide)-bl-poly(methylene carbonate), wherein:
less than 10% of the microparticles degrade under physiological conditions to release a therapeutic amount of the bioactive agent within 1 week of administration and more than 90% of the microparticles degrade under physiological conditions to release a therapeutic amount of the bioactive agent within 12 months of administration, and
wherein at least 99% of the microparticles become entrapped in the glomeruli of the kidney upon administration upon administration of the microparticles.